Galderma presents three-year Nemluvio data and Galderma stock costs EUR 178.18

Published on 10/12/2026 at 09:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma reported an 80.00 percent EASI-90 response at Week 152 on October 8, 2026. Galderma stock costs EUR 178.18 on October 12, 2026.

Key points in brief

Galderma presented three-year Nemluvio data on October 8, 2026, including an 80.00 percent EASI-90 response at Week 152.
First-half 2026 net sales rose 24.60 percent, while full-year growth guidance increased to 19.00-21.00 percent from 17.00-20.00 percent.
Galderma stock was trading at EUR 178.18 at Lang & Schwarz on October 12, 2026, at 9:45 a.m. CEST.
Galderma has a CHF 38.7 billion market capitalization and is listed on the SIX Swiss Exchange and in the SMI.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma presented new three-year Nemluvio data on October 8, 2026, and Galderma stock was trading at EUR 178.18 at Lang & Schwarz on October 12, 2026, at 9:45 a.m. CEST. According to Galderma, 80.00 percent of early responders achieved at least a 90.00 percent improvement in disease severity at Week 152.

Nemluvio delivers three-year responses

The company said the ARCADIA long-term extension analysis covered 295 patients who had responded by Week 16. At Week 152, 76.00 percent had clear or almost clear skin, 80.00 percent achieved EASI-90, and 50.00 percent reached complete skin clearance, according to Galderma.

The same October 8, 2026 release reported additional ARCADIA data from 1,903 adults and adolescents. Up to 91.00 percent achieved EASI-75, while up to 67.00 percent achieved clear or almost clear skin, giving investors a broader measure of Nemluvio's potential beyond the early-responder group.

Three dated milestones

On April 22, 2026, Galderma shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share, according to Galderma. On September 21, 2026, MarketScreener reported that Galderma entered the SMI and lifted full-year 2026 net sales growth guidance to 19.00-21.00 percent from 17.00-20.00 percent. The October 8 Nemluvio release then supplied the latest clinical figure, with 80.00 percent of early responders reaching EASI-90 at Week 152.

What does Nemluvio add?

The figures point to durability rather than a short-lived treatment response: 80.00 percent of early responders remained at EASI-90 after 152 weeks, while 50.00 percent achieved complete skin clearance. Galderma also reported no new safety signals in the three-year ARCADIA analysis, a relevant counterweight to the commercial opportunity because long-term tolerability supports continued treatment.

Next date is October 22

MarketScreener lists October 22, 2026, for Galderma's third-quarter business update. The date gives the next scheduled checkpoint for testing whether the 24.60 percent first-half 2026 net sales growth and the raised 19.00-21.00 percent full-year outlook are translating into the second half.

Stock price and company value

Galderma stock was trading at EUR 178.18 at Lang & Schwarz on October 12, 2026, at 9:45 a.m. CEST. The company's market capitalization was CHF 38.7 billion as of October 12, 2026, while the primary listing is on the SIX Swiss Exchange.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.